Still more Republican lawmakers are urging the U.S. trade representative to require Colombia to change its laws governing drug approvals before supporting the country’s membership in the Organization for Economic Cooperation and Development, an intergovernmental trade group.

In a letter late last week, U.S. Reps. Tom Rice (R-S.C.) and Patrick Meehan (R-Pa.) argued that the Colombian government must alter a national development plan, because it differs from World Health Organization standards by tying marketing approval for approving drugs to pricing criteria, which they argue is not used by other OECD countries. There are three dozen countries in the group.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy